<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03074890</url>
  </required_header>
  <id_info>
    <org_study_id>TRAMA-05-2014</org_study_id>
    <nct_id>NCT03074890</nct_id>
  </id_info>
  <brief_title>Evaluating of the Hospital Universitario de Canarias Massive Transfusion Protocol</brief_title>
  <acronym>PHM</acronym>
  <official_title>Observational Study to Assess the Safety and Clinical Effectiveness of the Hospital Universitario de Canarias Massive Transfusion Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Canarias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario de Canarias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Massive haemorrhage is defined as the necessity of 3 or more packed red blood cells in one
      hour, the transfusion of 10 packed blood cells, the loss of the half of the blood volume, the
      loss of 4-5 cc/kg/h or more, and haemorrhage shock.

      Haemorrhage shock provokes changes in the bloodstream with celular and organic disfunction.
      In many cases massive transfusion is needed to stabilize the vital function. This massive
      transfusion can have serious side effects (infectious and immunologic and no immunologic
      reactions) and increase the morbidity and mortality.

      Massive transfusion protocols improve the survival in severe trauma injury patients. The
      transfusion of fixed rate of packed red blood cells, fresh frozen plasma and platelet
      concentrates have decreased the severity of trauma induced coagulopathy.

      Recently several studies have shown the benefit of massive transfusion protocols with high
      transfusion ratios (1:1:1 RBC:FFP:PLT) in mortality after severe trauma. So early and
      aggressive transfusion improve the outcomes and the resources.

      Massive Transfusion Protocol have been elaborated in the Hospital Universitario de Canarias
      with high transfusion ratios (1:1:1 RBC:FFP:PLT) . The goals of this protocol is to reduce
      the variability in the clinic experience, to reduce the transfusion necessities and to assure
      an safe treatment with blood products.

      So with this study the investigators will evaluate if the goals of this Protocol are followed
      and if the use of this Protocol is really safe and efficient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day Mortality</measure>
    <time_frame>First 30 day after massive transfusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Hemostasis</measure>
    <time_frame>admission to hospital discharge or 30 days, whichever comes first</time_frame>
    <description>Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete)following emergency department arrival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Massive Transfusion Related Serious Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Immunological reactions No immunological reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of coagulopathy associated with high transfusion ratios</measure>
    <time_frame>30 days post admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Blood Products Given to Hemostasis</measure>
    <time_frame>24 hours from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Blood Products Given From Hemostasis to 24 Hours After</measure>
    <time_frame>24 hours after admission</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Massive Transfusion</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Intervention (cases)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC:FFP:PLT) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intervention (control))</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>all patients with massive haemorrhage in which the massive transfusion protocol didn´t apply</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Application Protocol</intervention_name>
    <description>Application lMassive Transfusion Protocol</description>
    <arm_group_label>Intervention (cases)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with massive haemorrhage and surgery

          -  Informed consent

        Exclusion Criteria:

          -  &lt;18 years old patients

          -  Patients didn´t want to participate in this study

          -  Patients were participated in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanesa González Fariña, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan J Jiménez Rivera, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José M Raya Sánchez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanesa González Fariña, MD</last_name>
    <email>vanefari@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María Martín Lorenzo, MD</last_name>
    <email>mcmartín-lorenzo@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Universitario de Canarias</name>
      <address>
        <city>La Laguna del Marquesado</city>
        <state>Santa Cruz de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magali Gonzaàlez- Colaço Harmand, MD,PhD</last_name>
      <phone>34922678115</phone>
      <email>magaligch@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ana Aldea, MD, PhD</last_name>
      <phone>34922678115</phone>
      <email>a.aldea@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vanesa González Fariña, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Martín Lorenzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nuria Montón Giménez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Gordini G, Stahel PF, Hunt BJ, Komadina R, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R; Task Force for Advanced Bleeding Care in Trauma. Management of bleeding following major trauma: a European guideline. Crit Care. 2007;11(1):R17. Erratum in: Crit Care. 2007 Apr 24;11(2):414.</citation>
    <PMID>17298665</PMID>
  </reference>
  <reference>
    <citation>Malone DL, Hess JR, Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma. 2006 Jun;60(6 Suppl):S91-6.</citation>
    <PMID>16763487</PMID>
  </reference>
  <reference>
    <citation>Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekley AC, Sebesta J, Jenkins D, Wade CE, Holcomb JB. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007 Oct;63(4):805-13.</citation>
    <PMID>18090009</PMID>
  </reference>
  <reference>
    <citation>Leal-Noval SR, Muñoz M, Asuero M, Contreras E, García-Erce JA, Llau JV, Moral V, Páramo JA, Quintana M; Spanish Society of Anaesthesiology and Reanimation (SEDAR); Spanish Society of Haematology and Haemotherapy (SEHH); Spanish Society of Hospital Pharmacy (SEFH); Spanish Society of Intensive Care, Critical and Coronary Units (SEMICYUC); Spanish Society of Thrombosis and Haemostasis (SETH); Spanish Society of Blood Transfusion (SETS). [2013: The Seville document on consensus on the alternatives to allogenic blood transfusion. Update to the Seville document. Spanish Societies of Anaesthesiology (SEDAR), Haematology and Haemotherapy (SEHH), Hospital Pharmacy (SEFH), Critical Care Medicine (SEMICYUC), Thrombosis and Haemostasis (SETH) and Blood Transfusion (SETS)]. Farm Hosp. 2013 May-Jun;37(3):209-35. doi: 10.7399/FH.2013.37.3.133. Spanish.</citation>
    <PMID>23789799</PMID>
  </reference>
  <reference>
    <citation>Cotton BA, Au BK, Nunez TC, Gunter OL, Robertson AM, Young PP. Predefined massive transfusion protocols are associated with a reduction in organ failure and postinjury complications. J Trauma. 2009 Jan;66(1):41-8; discussion 48-9. doi: 10.1097/TA.0b013e31819313bb.</citation>
    <PMID>19131804</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <last_update_submitted>March 5, 2017</last_update_submitted>
  <last_update_submitted_qc>March 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario de Canarias</investigator_affiliation>
    <investigator_full_name>María del Carmen Martín Lorenzo</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

